Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma

References

• Shi Y, Han Y, Yang J, et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res. 2019;31(1):152–161. doi:10.21147/j.issn.1000-9604.2019.01.10
   PubMed Web of Science ®Google Scholar
• O’Neill BP, O’Fallon JR, Earle JD, et al. Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys. 1995;33(3):663–673. doi:10.1016/0360-3016(95)00207-F
   PubMed Web of Science ®Google Scholar
• Mead GM, Bleehen NM, Gregor A, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer. 2000;89(6):1359–1370. doi:10.1002/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Biccler JL, Savage KJ, Brown PDN, et al. Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. Leuk Lymphoma. 2019;60(10):2516–2523. doi:10.1080/10428194.2019.1594219
   PubMed Web of Science ®Google Scholar
• Eloranta S, Brånvall E, Celsing F, et al. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013. Eur J Haematol. 2018;100(1):61–68. doi:10.1111/ejh.12980
   PubMed Web of Science ®Google Scholar
• Sehn LH, Martelli M, Trněný M, et al. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13(1):71. doi:10.1186/s13045-020-00900-7
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31(4):846–852. doi:10.1038/leu.2016.334
   PubMed Web of Science ®Google Scholar
• Houillier C, Ghesquières H, Chabrot C, et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neurooncol. 2017;133(2):315–320. doi:10.1007/s11060-017-2435-7
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Yamaguchi S, Motegi H, et al. Long-term evaluation of combination treatment of single agent HD-MTX chemotherapy up to three cycles and moderate dose whole brain irradiation for primary CNS lymphoma. Chemother. 2019;31(1):35–41. doi:10.1080/1120009X.2018.1546984
   Web of Science ®Google Scholar
• Chen C, Sun P, Cui J, et al. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: a retrospective study from China. Cancer Med. 2019;8(4):1359–1367. doi:10.1002/cam4.1906
   PubMed Web of Science ®Google Scholar
• Sun X, Liu J, Wang Y, et al. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. Oncotarget. 2017;8(30):49156–49164. doi:10.18632/oncotarget.17101
   PubMedGoogle Scholar
• Han X, Ji Y, Ouyang M, et al. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese. Sci Rep. 2017;7(1):17053, doi:10.1038/s41598-017-17359-1
   PubMedGoogle Scholar
• Schorb E, Fox CP, Kasenda B, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020;189(5):879–887. doi:10.1111/bjh.16451
   PubMed Web of Science ®Google Scholar
• Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297–1303. doi:10.1093/neuonc/now033
   PubMed Web of Science ®Google Scholar
• Mao C, Chen F, Li Y, et al. Characteristics and outcomes of primary central nervous system lymphoma: a retrospective study of 91 cases in a Chinese population. World Neurosurg. 2019;123:e15–e24. doi:10.1016/j.wneu.2018.10.034
   PubMed Web of Science ®Google Scholar
• Alnahhas I, Jawish M, Alsawas M, et al. Autologous stem-cell transplantation for primary central nervous system lymphoma: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19(3):e129–e141. doi:10.1016/j.clml.2018.11.018
   PubMed Web of Science ®Google Scholar
• Schenone L, Houillier C, Tanguy ML, et al. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network. Bone Marrow Transplant. 2022;57(6):966–974. doi:10.1038/s41409-022-01648-z
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma. J Neurooncol. 2016;126(3):545–550. doi:10.1007/s11060-015-1994-8
   PubMed Web of Science ®Google Scholar
• Zhang JP, Lee EQ, Nayak L, et al. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol. 2013;115(1):71–77. doi:10.1007/s11060-013-1196-1
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol. 2019;30(4):621–628. doi:10.1093/annonc/mdz032
   PubMed Web of Science ®Google Scholar
• Tun HW, Johnston PB, DeAngelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018;132(21):2240–2248. doi:10.1182/blood-2018-02-835496
   PubMed Web of Science ®Google Scholar
• Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121–130. doi:10.1016/j.ejca.2019.05.024
   PubMed Web of Science ®Google Scholar
• Terziev D, Hutter B, Klink B, et al. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma. Eur J Haematol. 2018;101(1):115–118. doi:10.1111/ejh.13072
   PubMed Web of Science ®Google Scholar
• Frutoso M, Mortier E. NK cell hyporesponsiveness: more is not always better. Int J Mol Sci. 2019;20(18):4514, doi:10.3390/ijms20184514
   PubMed Web of Science ®Google Scholar
• Shaffer BC, Le Luduec JB, Park S, et al. Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML. Blood Adv. 2021;5(7):2003–2011. doi:10.1182/bloodadvances.2020002701
   PubMed Web of Science ®Google Scholar
• Li L, Kolk M, Fernandez-Vina M, et al. Interrogating the impact of KIR ligand mismatch in engraftment following HLA-disparate stem cell transplantation. Bone Marrow Transplant. 2020;55(12):2294–2297. doi:10.1038/s41409-020-0957-7
   PubMed Web of Science ®Google Scholar
• Marra J, Greene J, Hwang J, et al. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia. J Immunol. 2015;194(9):4222–4230. doi:10.4049/jimmunol.1402124
   PubMed Web of Science ®Google Scholar
• Erbe AK, Wang W, Carmichael L, et al. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. J Immunother Cancer. 2019;7(1):70. doi:10.1186/s40425-019-0538-8
   PubMed Web of Science ®Google Scholar
• Forlenza CJ, Boudreau JE, Zheng J, et al. KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma. J Clin Oncol. 2016;34(21):2443–2451. doi:10.1200/JCO.2015.64.9558
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–5043. doi:10.1200/JCO.2005.13.524
   PubMed Web of Science ®Google Scholar
• Vilches C, Castaño J, Gómez-Lozano N, et al. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens. 2007;70(5):415–422. doi:10.1111/j.1399-0039.2007.00923.x
   PubMedGoogle Scholar
• Smith LK. HLA typing by direct DNA sequencing. Methods Mol Biol. 2012;882:67–86. doi:10.1007/978-1-61779-842-9_5
   PubMedGoogle Scholar
• Robinson J, Halliwell JA, McWilliam H, et al. IPD–the immuno polymorphism database. Nucleic Acids Res. 2013;41(Database issue):D1234–D1240. doi:10.1093/nar/gks1140
   PubMedGoogle Scholar
• Yuan XG, Huang YR, Yu T, et al. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases. Ann Hematol. 2020;99(1):93–104. doi:10.1007/s00277-019-03821-9
   PubMed Web of Science ®Google Scholar
• Kim N, Lim DH, Yoon SE, et al. Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma. J Neurooncol. 2022;156(2):307–316. doi:10.1007/s11060-021-03909-1
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510–e523. doi:10.1016/S2352-3026(17)30174-6
   PubMed Web of Science ®Google Scholar
• Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematol Am Soc Hematol Educ Program. 2017;2017(1):565–577. doi:10.1182/asheducation-2017.1.565
   PubMed Web of Science ®Google Scholar
• Chiesa S, Hohaus S, Falcinelli L, et al. Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy. Ann Hematol. 2020;99(10):2367–2375. doi:10.1007/s00277-020-04220-1
   PubMed Web of Science ®Google Scholar
• Birsen R, Willems L, Pallud J, et al. Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients. Haematologica 2018;103(7):e296–e299. doi:10.3324/haematol.2017.185843
   PubMed Web of Science ®Google Scholar
• Renaud L, Bossard JB, Carpentier B, et al. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Eur J Haematol. 2021;107(3):370–373. doi:10.1111/ejh.13667
   PubMed Web of Science ®Google Scholar
• Sekine T, Marin D, Cao K, et al. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016;128(2):297–312. doi:10.1182/blood-2016-03-706317
   PubMed Web of Science ®Google Scholar
• van der Ploeg K, Luduec L, Stevenson JB, et al. HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation. Blood Adv. 2020;4(19):4955–4964. doi:10.1182/bloodadvances.2020002086
   PubMed Web of Science ®Google Scholar
• Boudreau JE, Giglio F, Gooley TA, et al. KIR3DL1/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation. J Clin Oncol. 2017;35(20):2268–2278. doi:10.1200/JCO.2016.70.7059
   PubMed Web of Science ®Google Scholar
• Ruscetti M, Leibold J, Bott MJ, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018;362(6421):1416–1422. doi:10.1126/science.aas9090
   PubMed Web of Science ®Google Scholar
• Chang MC, Cheng HI, Hsu K, et al. NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia. Front Immunol. 2019;9:3152, doi:10.3389/fimmu.2018.03152
   PubMed Web of Science ®Google Scholar
• Wei B, Liu Z, Fan Y, et al. Analysis of cellular heterogeneity in immune microenvironment of primary central nervous system lymphoma by single-cell sequencing. Front Oncol. 2021;11:683007, doi:10.3389/fonc.2021.683007
   PubMed Web of Science ®Google Scholar
• Lin Z, Ma J, Ma Y, et al. Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma. Front Immunol Published Online. 2023;14. doi:10.3389/fimmu.2023.1191033
   Web of Science ®Google Scholar